Navigation Links
United Therapeutics Reports Second Quarter 2008 Financial Results

- Revenues of $68.6 Million, Increase of 32% Over Second Quarter 2007 - EPS of $0.63 per Basic Share, Increase of 125% Over Second Quarter 2007 - Earnings Before Non-Cash Charges of $1.36 per Basic Share, Increase of

56% Over Second Quarter 2007

SILVER SPRING, Md., July 31 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its results of operations for the quarter ended June 30, 2008.

Total revenues for the second quarter of 2008 were $68.6 million, up 32.3% from $51.8 million for the second quarter of 2007. Net income for the second quarter of 2008 was $14.3 million, or $0.63 per basic share, compared to $5.8 million, or $0.28 per basic share, for the second quarter of 2007. Gross margins from sales were $60.6 million in the second quarter of 2008, compared to $45.8 million in the second quarter of 2007. The increases in revenues and gross margins corresponded to the growth in sales of our lead product, Remodulin. Earnings before non-cash charges, defined as net income before non-cash income taxes, depreciation, amortization, impairment charges and share-based compensation (stock option and share tracking award expense), were $30.7 million for the second quarter of 2008, up 70.3% from $18.0 million for the second quarter of 2007.

"It is gratifying that we are on track to grow our annual revenues in excess of 30% for the sixth consecutive year," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "I am also pleased that, after twelve years of operations, our accumulated deficit has been eliminated and we are now able to report accumulated earnings. These financial accomplishments reflect the decisions of hundreds of doctors and patients to use Remodulin and make it the leading form of prostacyclin therapy in the United States."

Research and Development Expenses

The table below summarizes research and development expenses by major project and non-project components (dollars in thousands):

Three Months Ended

June 30,


2008 2007


Project and non-project:

Cardiovascular $11,890 $ 9,269 28.3 %

Cancer 177 4,061 (95.6)%

Infectious disease 220 200 10.0 %

Share-based compensation 3,313 2,981 11.1 %

Other 3,541 1,459 142.7 %

Total research and

development expense $19,141 $17,970 6.5 %

The increase in cardiovascular expenses was primarily due to increased expenses related to our inhaled and oral treprostinil programs.

Selling, General and Administrative Expenses

The table below summarizes selling, general and administrative expenses by major category (dollars in thousands):

Three Months Ended

June 30,


2008 2007



General and administrative $9,444 $9,066 4.2 %

Sales and marketing 9,316 5,708 63.2 %

Share-based compensation 4,333 5,700 (24.0)%

Total selling, general

and administrative expenses $23,093 $20,474 12.8 %

The increase in sales and marketing related expenses reflects increases in salary and related expenses and professional fees incurred in connection with new marketing campaigns and initiatives.

Earnings Before Non-Cash Charges

The following table provides a reconciliation of net income to earnings before non-cash charges for the three-month periods ending June 30, 2008 and 2007, respectively (in thousands, except per share data):

Three Months Ended

June 30,

2008 2007

Net income, as reported $14,331 $5,806

Add back:

Income tax expense 7,553 2,724

Depreciation and amortization 1,028 796

Impairment charges 152 -

Share-based compensation 7,661 8,714

Earnings before non-cash charges $30,725 $18,040

Earnings before non-cash charges per share (1):

Basic $1.36 $0.87

Diluted $1.26 $0.82

(1) Calculated by dividing earnings before non-cash charges by the

weighted average shares outstanding, as reported below.

Conference Call

United Therapeutics will host a half-hour teleconference on Thursday, July 31, 2008, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-800-603-1777, with international callers dialing 1-706-679-8129. A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 1-800-642-1687, with international callers dialing 1-706-645-9291, and using conference code: 56186490.

This teleconference is also being webcast and can be accessed via United Therapeutics' website at

About United Therapeutics

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.

Non-GAAP Financial Information

This press release contains a financial measure that does not comply with U.S. generally accepted accounting principals (GAAP). This measure supplements our financial results prepared in accordance with GAAP as reported below.

We use earnings before non-cash charges, a financial non-GAAP measure, internally for operating, budgeting and financial planning purposes and as a metric to determine the efficiency of our operations. We believe our investors' understanding of our performance is enhanced by disclosing this measure. The presentation of this non-GAAP financial measure is not to be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP.

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our expectations and intentions related to annual revenue growth and our ability to maintain our accumulated earnings. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and current reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of July 31, 2008, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

Remodulin is a registered trademark of United Therapeutics Corporation. [uthr-g]



(In thousands, except per share data)

Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007

(Unaudited) (Unaudited)


Net product sales $65,497 $49,381 $124,650 $87,788

Service sales 2,393 1,783 4,620 3,545

Distributor fees 666 667 1,333 667

Total revenues 68,556 51,831 130,603 92,000

Operating expenses:

Research and

development 19,141 17,970 40,217 46,084

Selling, general

and administrative 23,093 20,474 42,424 35,638

Cost of product sales 6,564 4,791 12,739 8,606

Cost of service sales 768 551 1,479 1,132

Total operating

expenses 49,566 43,786 96,859 91,460

Income from

operations 18,990 8,045 33,744 540

Other income (expense):

Interest income 2,804 1,938 6,412 5,983

Interest expense - (713) - (1,424)

Equity loss in

affiliate (43) (79) (156) (193)

Other, net 817 (279) 525 (220)

Total other income,

net 3,578 867 6,781 4,146

Income before income tax 22,568 8,912 40,525 4,686

Income tax expense (8,237) (3,106) (14,792) (1,661)

Net income $14,331 $ 5,806 $25,733 $3,025

Net income per common


Basic $0.63 $0.28 $1.15 $0.14

Diluted $0.59 $0.26 $1.07 $0.14

Weighted average number

of common shares


Basic 22,600 20,837 22,467 21,069

Diluted 24,328 22,020 24,120 22,219


As of June 30, 2008

(Unaudited, in thousands)

Cash, cash equivalents and marketable investments

(excluding restricted amounts of $45,037) $342,741

Total assets $679,818

Total liabilities & common stock subject to repurchase $316,411

Total stockholders' equity $363,407

SOURCE United Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
2. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
3. United Therapeutics to Announce Second Quarter 2008 Financial Results Before Market Open on Thursday, July 31, 2008
4. Animetrics Inc. Selected to Provide 3D Face Viewer Technology for United States Army Biometric Automated Toolset (BAT)
5. Warburg Pincus Acquires 5.4% of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank
6. Genzyme Files Applications for Approval of Mozobil in the United States and Europe
7. Sturgeon and Caviar From Aquaculture: United Food Technologies AG Hands Over Turnkey Plant
8. United Therapeutics Announces the Results of Its 2008 Annual Meeting of Shareholders
9. United Therapeutics Reports First Quarter 2008 Financial Results
10. United Therapeutics to Announce First Quarter 2008 Financial Results Before Market Open on Thursday, May 1, 2008
11. United BioSource Acquires Leading Publication Planning Software and Services Company
Post Your Comments:
(Date:5/20/2016)... ... ... The recent recall by Costco and Trader Joes of 47 million pounds of ... demonstrates the need for faster and more cost effective bio-threat detection to ensure food ... , PathSensor’s latest solution uses a biosensor technology called CANARY®. CANARY®, an ...
(Date:5/19/2016)... There is no saying when ... relentless pressures in pricing and lack in consumer confidence. ... though - numerous opportunities are up for grabs but ... presents four names in this sector: Portola Pharmaceuticals Inc. ... VTAE ), Anthera Pharmaceuticals Inc. (NASDAQ: ...
(Date:5/19/2016)... , May 19, 2016 - ... sessione orale durante il 52 ° ... 8006)    - Le conclusioni dello studio ... i pazienti trattati, di cui il 90% presenta una d ... mesi o più. Il settantadue per cento dei pazienti ha ...
(Date:5/18/2016)... , May 18, 2016 The ... it does not mean that there are no opportunities ahead. ... Pharmaceuticals Inc. (NASDAQ: THLD ), Seattle Genetics Inc. ... CHMA ), and Ophthotech Corp. (NASDAQ: OPHT ). ... alerts at: Threshold ...
Breaking Biology Technology:
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):